Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The objective of this international, 8-week, randomized, double-blind study was to show the superiority of the antidepressant efficacy of agomelatine, the first MT1/MT2 receptor agonist and 5-HT2C receptor antagonist antidepressant, versus fluoxetine in outpatients fulfilling Diagnostic and Statistical Manual of Mental Disorders-volume IV-TR criteria for major depressive disorder of severe intensity, defined by a baseline Hamilton Depression Rating Scale (HAM-D17) total score of at least 25 and CGI severity of illness score of at least 4. Patients received agomelatine 25-50 mg/day (n=252) or fluoxetine 20-40 mg/day (n=263) for 8 weeks. The main efficacy outcome measure was HAM-D17 total score (change from baseline to last post-baseline assessment). Secondary outcome measures were Clinical Global Impressions-improvement (CGI), severity (CGI-S), anxiety (HAM-A), and sleep (HAM-D sleep items) scores. The mean decrease in HAM-D17 total score over 8 weeks was significantly greater with agomelatine than fluoxetine with a between-group difference of 1.49 (95% confidence interval, 0.20-2.77; P=0.024). The percentage of responders at last post-baseline assessment was higher with agomelatine on both HAM-D17 (decrease in total score from baseline ≥50%; 71.7% agomelatine vs. 63.8% fluoxetine; P=0.060) and CGI-improvement (score 1 or 2; 77.7 vs. 68.8%; P=0.023). There was a significant between-group difference of 0.37 (95% confidence interval, 0.06-0.68) in HAM-D sleep subscore in favor of agomelatine (P=0.018). Similar improvements were observed on HAM-A with agomelatine and fluoxetine. Both treatments were safe and well tolerated. In conclusion, in this study, agomelatine showed superior antidepressant efficacy over fluoxetine in treating patients with a severe episode of major depressive disorder after 8 weeks of treatment with a good tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Place of chronic insomnia in the course of depressive and anxiety disorders
Ohayon, M. M., & Roth, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00052-3 · Cited by 873 · cited 1×
“Sleep disturbances constitute an important component of depression, and their improvement should be a feature of antidepressant therapy in patients with MDD (Ohayon and Roth, 2003).”
BackgroundSouêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396 · cited 2×
“…et al., 1997; Leproult et al., 2005), and to re-establish normal circadian rhythms early in treatment of depressed patients (Quera Salva et al., 2007; Kasper et al., 2010), which are frequently disturbed in depressed patients (Souetre et al., 1989; Peeters et al., 2006; Emens et al., 2009).”
BackgroundGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 1×
“There is also evidence of superior efficacy for venlafaxine, when compared with SSRIs as a class and with fluoxetine individually (Hansen et al., 2005; Papakostas et al., 2007; Nemeroff et al., 2008).”
BackgroundDiurnal mood variation in major depressive disorder
Peeters, F., Berkhof, J., Delespaul, P., Rottenberg, J., & Nicolson, N. A. (2006) · Emotion · doi:10.1037/1528-3542.6.3.383 · Cited by 306 · cited 2×
“…et al., 1997; Leproult et al., 2005), and to re-establish normal circadian rhythms early in treatment of depressed patients (Quera Salva et al., 2007; Kasper et al., 2010), which are frequently disturbed in depressed patients (Souetre et al., 1989; Peeters et al., 2006; Emens et al., 2009).”
BackgroundCircadian misalignment in major depressive disorder
Emens, J., Lewy, A., Kinzie, J. M., Arntz, D., & Rough, J. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.04.009 · Cited by 253
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Leproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167 · cited 2×
“…resynchronize altered circadian rhythms both in an animal model of depression (Fuchs et al., 2006) and in healthy volunteers (Krauchi et al., 1997; Leproult et al., 2005), and to re-establish normal circadian rhythms early in treatment of depressed patients (Quera Salva et al., 2007; Kasper et…”
Background
Cited by
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Circadian rhythms and depression: Human psychopathology and animal models
Kronfeld-Schor, N., & Einat, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.020 · Cited by 166
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
“In contrast, the individual head to head studies comparing with selective serotonin reuptake inhibitor (SSRI) and serotonin– noradrenaline reuptake inhibitor (SNRI) antidepressants have reported superior efficacy compared with fluoxetine (Hale et al., 2010), sertraline (Kasper et al.”
ResultCircadian Rhythms, Melatonin and Depression
A. Quera Salva, M., Hartley, S., Barbot, F., C. Alvarez, J., Lofaso, F., & Guilleminault, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796197188 · Cited by 100
Corruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000679 · Cited by 94
“, 2010); its antidepressant efficacy, demonstrated at doses of 25–50mg/d in patients with MDD (Olie and Kasper, 2007; Goodwin, 2009), has been compared previously with other antidepressants of different classes (Lemoine and Guilleminault, 2007; Hale et al., 2010; Kasper et al., 2010).”
ResultRole of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Stefanovics, E. A., Rosenheck, R. A., Jones, K. M., Huang, G., & Krystal, J. H. (2018) · Psychiatric Quarterly · doi:10.1007/s11126-017-9522-y · Cited by 74
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Metadata
- Authors
- Hale, A., Corral, R.-M., Mencacci, C., Ruiz, J. S., Severo, C. A., & Gentil, V.
- Venue
- International Clinical Psychopharmacology
- Published
- 2010-11
- Volume
- 25
- Issue
- 6
- Pages
- 305-314
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1988123141
- Cited by
- 127
- References
- 11
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.